LOS ANGELES, Feb. 15 (Xinhua) — The U. S. National Institutes of Health (NIH) is working on a national institute. The U. S. Department of Health and Prevention has submitted a multi-site clinical trial comparing an experimental antiviral for COVID-19 remedy, the firm said today.
The treatment, known as S-217622 or ensitrelvir fumaric acid, was discovered by Hokkaido University in Japan; and shionogi
The trial evaluates whether S-217622 can produce clinical outcomes in patients hospitalized for COVID-19 control compared to placebo. It will recruit approximately 1500 other people from all over the world.
S-217622 is the first agent to be evaluated in a new global adaptive clinical protocol known as Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE), according to the NIH.
“We hope that the effects of this trial can be implemented to improve the popularity of care for others with COVID-19, which still causes many deaths every day in the United States, as well as our pandemic preparedness,” H said. said Clifford. Lane, deputy director of clinical research and special projects at the U. S. National Institute of Allergy and Infectious Diseases. U. S.
“The STRIVE protocol and clinical study infrastructure can be adapted to compare other agents for COVID-19, such as remedies for other respiratory pathogens,” he said.